The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Novo Nordisk is attractively valued after the sell-off, but near-term recovery requires patience. Read why I'm downgrading ...

Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the ...

Financial report for the period 1 January 2025 to 30 June 2025                                                                                                                                          ...

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign ...

Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...